Raking In the Profits
Though I use technical analysis to guide buy and sell decisions, I also incorporate fundamentals into my screening processes. In fact, I have several screens that focus on various fundamental indicators. I may place stocks like these on an active watch list or, if the technicals are lacking, I might just monitor them on a regular basis.
One of last year's best large-cap earnings performers was biotech name Celgene (CELG). The company reported yearly income of $3.79 per share for 2011, a gain of 36%. This year, that number is expected to rise another 29% to $4.88 per share....404 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.